Abstract:Background: Metabolic syndrome (MetS) has been shown to have a negative impact on prostate cancer (PCa). However, there is limited research on the effects of MetS on testosterone levels in metastatic prostate cancer (mPCa). Objective: This study aims to investigate the influence of MetS, its individual components, and composite metabolic score on the prognosis of mPCa patients, as well as the impact on testosterone levels. Additionally, it seeks to identify MetS-related risk factors that could impact the time of decline in testosterone levels among mPCa patients. Methods: A total of 212 patients with mPCa were included in the study. The study included 94 patients in the Non-MetS group and 118 patients in the combined MetS group. To analyze the relationship between MetS and testosterone levels in patients with mPCa. Additionally, the study aimed to identify independent risk factors that affect the time for testosterone levels decline through multifactor logistic regression analysis. Survival curves were plotted by the Kaplan-Meier method. Results: Compared to the Non-MetS group, the combined MetS group had a higher proportion of patients with high tumor burden, T stage ≥ 4, and Gleason score ≥ 8 points (P < 0.05). Patients in the combined MetS group also had higher lowest testosterone values and it took longer for their testosterone to reach the lowest level (P < 0.05). The median progression-free survival (PFS) time for patients in the Non-MetS group was 21 months, while for those in the combined MetS group it was 18 months (P = 0.001). Additionally, the median overall survival (OS) time for the Non-MetS group was 62 months, whereas for the combined MetS group it was 38 months (P < 0.001). The median PFS for patients with a composite metabolic score of 0-2 points was 21 months, 3 points was 18 months, and 4-5 points was 15 months (P = 0.002). The median OS was 62 months, 42 months, and 29 months respectively (P < 0.001). MetS was found to be an independent risk factor for testosterone levels falling to the lowest value for more than 6 months. The risk of testosterone levels falling to the lowest value for more than 6 months in patients with MetS was 2.157 times higher than that of patients with Non-MetS group (P = 0.031). Patients with hyperglycemia had a significantly higher lowest values of testosterone (P = 0.015). Additionally, patients with a BMI ≥ 25 kg/m2 exhibited lower initial testosterone levels (P = 0.007). Furthermore, patients with TG ≥ 1.7 mmol/L experienced a longer time for testosterone levels to drop to the nadir (P = 0.023). The lowest value of testosterone in the group with a composite metabolic score of 3 or 4-5 was higher than that in the 0-2 group, and the time required for testosterone levels to decrease to the lowest value was also longer (P < 0.05). Conclusion: When monitoring testosterone levels in mPCa patients, it is important to consider the impact of MetS and its components, and make timely adjustments to individualized treatment strategies.

Correlation Between Metabolic Syndrome and Clinical Progression in Patients with Benign Prostatic Hyperplasia

The Relationship Between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study

The Correlation Between Metabolic Syndrome and Benign Prostatic Hyperplasia in Men over 50 Years O1d

Relationship between metabolic syndrome and benign prostatic hyperplasia

Relationship Between Benign Prostatic Hyperplasia and Metabolic Syndrome

Metabolic syndrome and metastatic prostate cancer correlation study, a real-world study in a prostate cancer clinical research center, Xinjiang, China

Relationship between lower urinary tract symptoms and metabolic syndrome in a Chinese male population

Metabolic Syndrome is Not Associated with Prostate Cancer Recurrence: A Retrospective Analysis of a Chinese Cohort.

The Association Between Metabolic Syndrome and Advanced Prostate Cancer in Chinese Patients Receiving Radical Prostatectomy

The influence of metabolic syndrome on the development and clinical manifestations of benign prostatic hyperplasia

Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention

The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome

Metabolic Syndrome and Its Components Predict the Biochemical Recurrence and Adverse Pathological Features of Patients Following Radical Prostatectomy: a Propensity Score Matching Study

Association Study Between Benign Prostatic Hyperplasia and Primary Hypertension

Correlation of Diabetes Control with Benign Prostatic Hyperplasia in T2DM Patients

Effect of metabolic syndrome on testosterone levels in patients with metastatic prostate cancer: a real-world retrospective study

Correlation Between Molecular Biomarkers and Risk Factors for the Clinical Progression of Benign Prostatic Hyperplasia Using Tissue Micro Array Immuno Staining

[Correlation of Benign Prostatic Hyperplasia with Hyperlipemia].

Correlation between metabolic syndrome and periurethral prostatic fibrosis: results of a prospective study

The Association Between Metabolic Syndrome and the National Institutes of Health Chronic Prostatitis Symptom Index: Results from 1673 Men in China

AB075. The relationship between benign prostatic hyperplasia/lower urinary tract symptoms and mean platelet volume: the role of metabolic syndrome